8-K current report · filed Oct 30, 2026

Harmony Biosciences Holdings, Inc. (HRMY) 8-K Current Report: October 30, 2026

Item 5.02HRMY overview

Short answer

Harmony Biosciences Holdings, Inc. (HRMY) filed an 8-K current report with the SEC on October 30, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Jeffrey M. Dayno departing, retained as advisor through January 31, 2028.

Harmony Biosciences Holdings, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Jeffrey M. Dayno departing, retained as advisor through January 31, 2028
  • Dayno consulting compensation: $500 per hour, continued equity vesting, or full vesting upon a change in control
  • Peter Anastasiou appointed President and CEO, signaling leadership succession at Harmony Biosciences
  • Anastasiou base salary $725,000, with 2027 target bonus opportunity equal to 75% of salary
  • New equity incentives: $1.75 million options and $750,000 restricted stock units, vesting over four years

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Harmony Biosciences Holdings, Inc. 8-K filings

Get the next HRMY 8-K as it lands

Follow HRMY for push alerts, or ask the research agent what this filing means.